港股午评 恒生指数早盘跌1.91% 自驾概念股逆市走高

Market Overview - The Hang Seng Index fell by 1.91%, down 490 points, closing at 25,138 points, while the Hang Seng Tech Index dropped by 2.41%. The early trading volume in Hong Kong was HKD 107.2 billion [1]. Autonomous Driving Sector - The Ministry of Industry and Information Technology of China officially announced the first batch of L3 conditional autonomous driving vehicle licenses, marking a significant step in the practical application of intelligent connected vehicles. Stocks related to smart driving rose against the market trend, with Zhejiang Shibao (01057) increasing by 13.9% and Youjia Innovation (02431) rising by 9.88% [1]. Pharmaceutical Sector - The innovative drug sector declined again, with a temporary vacuum in pharmaceutical BD transactions over the past six months. Notable declines included Innovent Biologics (09969) falling over 3.62% and I-Mab (01801) down by 2.39% [1]. Gold Sector - Gold stocks experienced a widespread decline. The BOCM index is set for rebalancing, and JPMorgan indicated that gold and silver face significant technical selling pressure. Zijin Mining International (02259) dropped by 5.93%, while Zijin Mining (02899) fell by 4.5% [1]. Solar Energy Sector - The solar energy sector weakened again, with the Solar Association confirming the establishment of a storage platform, while prices for solar glass remain under pressure. New Special Energy (01799) decreased by 2%, and Xinyi Solar (00968) fell by 3.6% [1]. Optical Communication Sector - Oracle's performance for the second fiscal quarter of 2026 fell short of market expectations, leading to a continuation of declines in the optical communication sector. Cambridge Technology (06166) and Yangtze Optical Fibre and Cable (06869) both dropped by over 5% [1]. ZTE Corporation - ZTE Corporation (00763) fell by over 4%, with the company adjusting some AI capabilities in its Doubao mobile assistant and recently announcing a significant share buyback [2]. Bole Technology - Bole Technology-B (02592) saw a decline of 11% after submitting a new drug clinical trial application for its ophthalmic candidate CBT-199 in the U.S. [3]. Domestic Beverage Sector - Hushang Ayi (02589) rose by over 4%, capitalizing on the growing trend of domestic new tea beverage brands expanding into international markets, specifically entering Malaysia and the U.S. [4].